Medigene and SynCore Biotechnology Co have expanded the existing exclusive licensing and supply contract into new regions for the supply and marketing of Veregen (sinecatechins 15% ointment) for the treatment of genital warts. Along with existing agreements in Taiwan, SynCore will now be responsible for the approval process and commercialisation of the drug for the treatment of genital warts throughout Asia (excluding China and Korea), Australia and New Zealand. In addition to income from the production and supply of the ointment and the active ingredient, Medigene will receive payment when specific milestones are reached. Medigene already has partnerships in Asia for the distribution of Veregen in China (GC Rise Pharmaceutials) and South Korea (Kolon Pharmaceuticals).
Veregen is already marketed in the US (by Fougera), in Germany, Austria, Switzerland (by Abbott) and Spain (by Bial). Market authorisation has been granted for other countries or is expected within the next few months.
|Agreement Status:||Updated||Date Announced:||20 Mar 2013|
|Date Last Reported:||18 May 2011||Duration:|
|Est Total Value:||Investment To Date:|
|Generic / Brand Name:||Veregen sinecatechins|
|Therapeutic Area:||General Anti-infectives Systemic Genito-urinary System and Sex Hormones|